glp-1 type 2 diabetes Receptor Agonists as Treatments for Glucagon-like peptide-1 and glucose-dependent insulinotropic
Description
The move targets insured patients as competition with Eli Lillys Zepbound heats up.
Biopharma bigwigs Eli Lilly and Novo Nordisk are upping capacity to meet the rising demands of GLP-1 drugs.
GLP-1 receptor agonists may cause dizziness or lightheadedness, especially during initial titration or dose increases
Mounjaro (tirzepatide) commonly causes digestive side effects such as nausea, diarrhea, and constipation
Discover the science behind Wegovy and how GLP-1 technology helps reduce appetite, improve metabolism, and support long-term weight loss
The ADA now recommends GLP1 RAs with proven benefit to slow CKD progression and reduce CV risk in people with type 2 diabetes
